Skip to main content
Mercury Laboratories Limited logo

Mercury Laboratories Limited — Investor Relations & Filings

Ticker · 538964 ISIN · INE947G01011 LEI · 98450068F40047C86C71 BSE.NS Manufacturing
Open in API
Filings indexed 418 across all filing types
Latest filing 2026-05-31 Regulatory Filings
Country IN India
Listing BSE.NS 538964

About Mercury Laboratories Limited

https://mercurylabs.com/

Mercury Laboratories Limited specializes in the development, manufacturing, and marketing of a diverse range of pharmaceutical formulations. Established in 1962, the company focuses on therapeutic segments including gynecology, pediatrics, cardiology, and orthopedics. Its product portfolio encompasses various dosage forms such as tablets, capsules, liquid orals, and injectables. The company operates WHO-GMP certified manufacturing facilities, ensuring adherence to international quality standards. Mercury Laboratories maintains a significant presence in both domestic and international markets, providing healthcare solutions through a robust distribution network. Key products include specialized treatments for maternal health and pediatric care, alongside general medicine offerings.

Recent filings

Filing Released Lang Actions
Newspaper publication of audited financial statement for the quarter and year ended on 31.03.2026 is attached
Regulatory Filings Classification · 90% confidence The document is a compliance submission under SEBI (LODR) Regulations, specifically a letter to the stock exchange enclosing newspaper cuttings of the audited results published under Regulation 47. It does not contain any actual financial data or full report, but rather is a regulatory notice of publication. This falls under the general regulatory filings category.
2026-05-31 English
Corrigendum to audited financial statement results for the quarter and year ended on 31.03.2026 is attached
Interim / Quarterly Report Classification · 80% confidence The document is a formal SEBI LODR filing of audited financial results (P&L, balance sheet, cash flow, and notes) for the quarter and year ended March 31, 2026, filed under Regulation 33. It contains full financial statements (not just headline earnings) but is not a full Annual Report (10-K) with MD&A, nor a simple earnings highlight (ER). This matches an interim/quarterly report (IR) filing that includes substantive financial data for a period shorter than a full fiscal year (quarterly results) and the year-end audited results. Therefore, it should be classified as an Interim / Quarterly Report (IR). FY 2026
2026-05-29 English
Details of Appointment of Internal Auditor and Cost auditor is attached
Regulatory Filings Classification · 85% confidence The document is a SEBI LODR Regulation 30 disclosure to the stock exchange announcing the appointment of internal and cost auditors. It is a regulatory compliance announcement with no substantive financial statements, not an audit report itself, not a board/management change, and no other specific filing category applies. It therefore falls under the general Regulatory Filings category (RNS).
2026-05-29 English
book colusre intimation for 45th AGM and Dividend is attached
Notice of Dividend Amount Classification · 78% confidence The document is an official notice to the stock exchange under SEBI LODR Regulations providing the book‐closure dates, record date and dividend rate for shareholders in advance of the 45th AGM and proposed final dividend. It is not an AGM presentation or minutes, nor an earnings announcement or interim report – it is specifically announcing dividend details and related record dates. Therefore it fits the “Notice of Dividend Amount” category.
2026-05-29 English
Recommendation of Dividend by the Board for the FY 2025-26
Interim / Quarterly Report Classification · 87% confidence The document is a SEBI LODR Regulation 30/33 submission reporting the outcome of a Board Meeting, primarily presenting the company’s audited financial results (profit & loss, assets & liabilities, cash flows and notes) for the quarter and financial year ended March 31, 2026. It contains full financial statements beyond mere highlights, but it is not a standalone Annual Report (10-K); rather it is the statutory quarterly/annual‐ended results announcement. This matches the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data for a period shorter than a full annual report. FY 2026
2026-05-29 English
Audited Financial results for the year ended on March 31, 2026 along with auditors report is attached
Earnings Release Classification · 82% confidence The document is an official ‘Outcome of Board Meeting’ filed under SEBI (LODR) Reg 30 and 33 to BSE, containing the audited financial results for the quarter and financial year ended March 31, 2026, along with full P&L, balance sheet, cash flow statement and auditors’ unmodified opinion. This is the company’s initial announcement of periodical (quarter & full‐year) financial results, matching an Earnings Release. FY 2026
2026-05-29 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.